ClinicalTrials.gg
RecruitingNCT06310551Updated Nov 5, 2026

First Time in Human Study of Long Acting VH4524184 Formulations

A Phase 1 interventional study of Oral VH4524184 and VH4524184 Formulation A SC in HIV Infections, sponsored by ViiV Healthcare. Recruiting at 5 sites in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 7 months later.
Updated Nov 5, 2026Primary completion movedStudy completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
348
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 266 studies in HIV Infections by GlaxoSmithKline — 15 open to participants now, 27 under way, 8 of them phase 3. HIV Infections · GlaxoSmithKline.

Planned enrollment
36th of 210
348 · median 82
Started
2024
with 10 others
Phase 1
83 of 266
9 open now
Primary completion
2029-05
later than 22 of 26 live
Registered
246th of 266
by date

Among the 266 studies in HIV Infections by GlaxoSmithKline, this one is the 36th largest by planned enrollment of the 210 interventional ones that give a count, is one of 11 that started in 2024, is one of 83 in phase 1, reaches primary completion later than 22 of the 26 other live ones, and was the 246th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

15 of the 266 studies in HIV Infections by GlaxoSmithKline are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 266 studies in HIV Infections by GlaxoSmithKline, or all of them as a file.
02

Study summary

The purpose of this study is to identify 1 or more doses of parenterally administered VH4524184 that are safe, well tolerated and yield a PK drug exposure profile necessary to deliver a long-acting antiretroviral therapy for the treatment of HIV-1 infection.

03

Conditions studied

  • HIV Infections

Browse trials for

Keywords

  • Safety
  • Tolerability
  • Parenteral
  • First Time in Human
  • Pharmacokinetics
  • Ascending Dose
  • Multiple Dose
  • Healthy Adults
04

Who can participate

The criteria were revised on the registry on Nov 5, 2026. See what changed

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Age

-Participant must be 18 to 55 years of age inclusive, at the time of signing the .

Type of Participant and Characteristics

  • Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring.
  • Participants who are able to understand and comply with protocol requirements and timetables, instructions, and protocol-stated restrictions.

Weight -Body weight ≥50.0 kg (110 lbs) for men and ≥45.0 kg (99 lbs) for women and within the range 18.5 to 32.0 kg/m\^2 (inclusive) for all cohorts except B19. For Cohort B19, body mass index within the range >32.0 to 37.0 kg/m\^2 (inclusive).

Sex and /Barrier Requirements

  • Male or female

    1. Male Participants: No restrictions for male participants
    2. Participants of female sex assigned at birth:

      • A participant of (POCBP) (female sex assigned at birth) is eligible to participate as long as the participant is not pregnant, breastfeeding and utilizes a highly effective method of contraception.
      • A participant of non-childbearing potential (PONCBP) is eligible to participate if all other eligibility criteria are met.

      Informed Consent

  • Capable of providing signed informed consent.

Exclusion criteria

Exclusion Criteria:

Medical Conditions

  • History or presence of clinical condition or disorder that could be capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study drug, interfering with the interpretation of data or would make the participant unsuitable for the study; unable to comply with dosing requirements; or unable to comply with study visits.
  • abnormal blood pressure as determined by the investigator.
  • Lymphoma, leukemia, or any within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of disease for 3 years.
  • Breast cancer within the past 10 years.
  • Current or chronic history of liver disease or known hepatic or biliary abnormalities.
  • Medical history of cardiac arrhythmias or cardiac disease or a family and personal history of long syndrome.
  • Underlying skin disease or disorder that would interfere with the administration of study product and/or assessment of injection site reactions.
  • Clinically significant history of drug , delayed-type hypersensitivity or severe hypersensitivity reactions, as well as history of /sensitivity to any of the study interventions including hyaluronidases.
  • Current or anticipated need for chronic anti-coagulation except for the use of low dose acetylsalicylic acid (≤325 mg) or hereditary coagulation and disorders such as hemophilia or Von Willebrand Disease.
  • History of seizure.
  • Any known or suspected pre-existing psychiatric condition, including depression, anxiety and insomnia/sleep disturbances, at the discretion of the investigator.
  • Any positive (abnormal) response confirmed by the investigator or clinician (or qualified designee) administered C-SSRS at screening.
  • Insufficient muscle mass (gluteus medius or thigh) to support IM dose administration in the opinion of the investigator.
  • Presence of tattoos, implants or skin piercings that may interfere with the administration of study product and/or assessment of ISRs, if they occur.
  • History of or on-going high-risk behaviors that may put the participant at increased risk for acquisition in the opinion of the investigator. This includes participants in HIV discordant relationships, or men who report current or prior unprotected anal sex with other men and those reporting prior or current injecting drug use.

Prior/Concomitant Therapy

  • Past or intended use of over-the-counter or prescription medication within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to dosing and for the duration of the study.
  • Receipt of any (s) within 28 days prior to screening or 14 days before or after scheduled SC or IM dosing.

Prior/Concurrent Clinical Study Experience

  • Exposure to more than 4 new products (including long-acting investigational products) within 12 months prior to the first dosing day.
  • Current enrollment or past participation in another investigational study in which an investigational intervention was administered within the last 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product before signing of consent (OR screening) any other clinical study.
  • Participation in the study would result in loss of blood in excess of 500 mL over a 56-day period.
  • Current enrollment or past participation in this clinical study, with the exception of participants who previously completed the Oral Lead In (OLI) but for operational or logistic reasons did not progress to CRU admission and receipt of injectable suspension for injection (SFI) or powder for suspension for injection (PFS) study medication or placebo, or prior participation in study 218803.

Diagnostic Assessments

  • \<60 mL/min or serum creatinine >1.1 x .
  • \<12.5 g/dL for men and \<11 g/dL for women
  • or AST > upper limit of normal (ULN).
  • Total >1.5xULN.
  • Any significant arrhythmia or finding.
  • Exclusion criteria for Screening ECG - a single repeat is allowed for eligibility determination.
  • Presence of and/or anti-HBc at Screening or within 3 months prior to first dose of study intervention.
  • Positive antibody test result at screening or within 3 months prior to first dose of study intervention.
  • Positive pre-study drug/alcohol screen.
  • Positive HIV antibody test.

Other Exclusions

  • Regular alcohol consumption within 6 months prior to the study defined as: An average weekly intake of >14 units for males or >7 units for females. One unit is equivalent to 8 g of alcohol: a half-pint (\~240 mL) of beer, 1 glass (125 mL) of wine or 1 (25 mL) measure of spirits.
  • Regular use of known drugs of abuse.
  • Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products within 6 months prior to screening and at admission.
  • Sensitivity to the study drug, or components thereof, or other drug or other allergy that, in the opinion of the investigator or Sponsor Medical Monitor, contraindicates participation in the study.
  • Fasting glucose >125 mg/dL (6.95 mmol/L) or receiving treatment for elevated blood glucose.
  • Triglycerides >500 mg/dL (5.7 mmol/L) or receiving treatment for dyslipidemia.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
348 participants (estimated)

Study arms

  • Experimental
    Formulation A SC Group

    Participants receive a Formulation A starting dose of VH4524184 LAI subcutaneously (SC).

    Drug: Oral VH4524184 · Drug: VH4524184 Formulation A SC · Drug: Placebo Formulation A SC · Drug: rHuPH20

  • Experimental
    Formulation B SC Group

    Participants receive a Formulation B starting dose of VH4524184 LAI subcutaneously (SC).

    Drug: Oral VH4524184 · Drug: rHuPH20 · Drug: VH4524184 Formulation B SC · Drug: Placebo Formulation B SC

  • Experimental
    Formulation A IM Group

    Participants receive a Formulation A starting dose of VH4524184 LAI intramuscularly (IM).

    Drug: Oral VH4524184 · Drug: VH4524184 Formulation A IM · Drug: Placebo Formulation A IM

  • Experimental
    Formulation B IM Group

    Participants receive a Formulation B starting dose of VH4524184 LAI intramuscularly (IM).

    Drug: Oral VH4524184 · Drug: VH4524184 Formulation B IM · Drug: Placebo Formulation B IM

  • Experimental
    Multiple doses Group

    VH4524184 LAI formulations administered SC or IM as single doses that achieve adequate PK exposure targets, may be evaluated for safety and tolerability as multiple doses.

    Drug: Oral VH4524184 · Drug: VH4524184 Formulation A SC · Drug: Placebo Formulation A SC · Drug: rHuPH20 · Drug: VH4524184 Formulation B SC · Drug: Placebo Formulation B SC · Drug: VH4524184 Formulation A IM · Drug: Placebo Formulation A IM · Drug: VH4524184 Formulation B IM · Drug: Placebo Formulation B IM

Interventions

  • DrugOral VH4524184

    VH4524184 to be taken orally.

  • VH4524184 LAI Formulation A administered subcutaneously.

  • DrugPlacebo Formulation A SC

    Placebo Formulation A administered subcutaneously.

  • rHuPH20 administered subcutaneously.

    Also known as: Halozyme ENHANZE

  • VH4524184 LAI Formulation B administered subcutaneously.

  • DrugPlacebo Formulation B SC

    Placebo Formulation B administered subcutaneously.

  • VH4524184 LAI Formulation A administered intramuscularly.

  • DrugPlacebo Formulation A IM

    Placebo Formulation A administered intramuscularly.

  • VH4524184 LAI Formulation B administered intramuscularly.

  • DrugPlacebo Formulation B IM

    Placebo Formulation B administered intramuscularly.

06

What researchers measure

Primary outcomes

  1. Percentage of participants reporting adverse events (AEs) and related AEs

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. Related AE = AE assessed by the investigator as related to the study drug.

    Time frame: From first study dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants

  2. Percentage of participants with AEs by severity

    Severity of AEs will be assessed using Division of AIDS Table for Grading the Severity of Adult Adverse Events (DAIDS). DAIDS grading scale is used to grade the toxicity associated with injection site reactions (ISR) including injection site pain (or tenderness), erythema (or redness), induration (or swelling), and pruritus. The toxicity level is graded from Grade 1 (lowest toxicity) to 4 (highest toxicity). Higher grade indicates higher toxicity.

    Time frame: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants

  3. Percentage of participants discontinuing the treatment due to AEs

    Time frame: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants

  4. Change from baseline in alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase parameters

    The liver panel laboratory parameters are assessed after the administration of long-acting injectable (LAI) VH4524184.

    Time frame: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants

  5. Change from baseline in total bilirubin parameters

    The liver panel laboratory parameters are assessed after the administration of LAI VH4524184.

    Time frame: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants

  6. Change from baseline in international normalized ratio (INR) parameters

    The liver panel laboratory parameters are assessed after the administration of LAI VH4524184.

    Time frame: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants

  7. Maximum toxicity grade increase from baseline in ALT, AST and alkaline phosphatase

    Time frame: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants

  8. Maximum toxicity grade increase from baseline in total bilirubin

    Time frame: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants

  9. Maximum toxicity grade increase from baseline in INR

    Time frame: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants

  10. Percentage of participants reporting injection site reaction (ISR) AEs

    Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, and Grade 4 = potentially life threatening.

    Time frame: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants

  11. Duration of injection site reaction AEs

    Time frame: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants

  12. Area under the concentration-time curve from time zero (pre-dose) extrapolated to infinity time (AUC[0-inf]) of LAI VH4524184 following single dose administration

    Time frame: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants

  13. Area under the plasma drug concentration-time curve from zero (pre-dose) to the end of the dosing interval at steady state (AUC[0-t]) of LAI VH4524184 following multiple dose administration

    Time frame: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants

  14. Maximum observed plasma drug concentration (Cmax) of LAI VH4524184 following single dose administration

    Time frame: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants

  15. Cmax of LAI VH4524184 following multiple dose administration

    Time frame: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants

  16. Time to maximum observed plasma drug concentration (Tmax) of LAI VH4524184 following single dose administration

    Time frame: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants

  17. Tmax of LAI VH4524184 following multiple dose administration

    Time frame: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants

  18. Apparent terminal half-life (t1/2) of LAI VH4524184 following single dose administration

    Time frame: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants

  19. t1/2 of LAI VH4524184 following multiple dose administration

    Time frame: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants

Secondary outcomes

  1. Percentage of participants with treatment emergent Grade 3 or Grade 4 laboratory abnormalities

    Grade 3 is defined as causing an inability to perform usual social \& functional activities with intervention or hospitalization indicated. Grade 4 is defined as an abnormality that is potentially life-threatening, causing an inability to perform basic self-care functions with intervention indicated to prevent permanent impairment, persistent disability, or death.

    Time frame: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants

07

Study locations

5 of 5 sites recruiting
  • GSK Investigational Site
    Lenexa, Kansas 66219, United States
    Recruiting
  • GSK Investigational Site
    Las Vegas, Nevada 89113, United States
    Recruiting
  • GSK Investigational Site
    Austin, Texas 78744, United States
    Recruiting
  • GSK Investigational Site
    San Antonio, Texas 78232, United States
    Recruiting
  • GSK Investigational Site
    Salt Lake City, Utah 84124, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.viiv-studyregister.com/documents/About_ViiV_Patient_Level_Data_Sharing_Final_28May2026.pdf

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.viiv-studyregister.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for May 2029, 62 months after the start.

Of 74 industry-sponsored phase 1 interventional studies under HIV Infections, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 18. This study's planned 62 months is above that.

Counting every sponsor, half of 165 studies reached it within 19 months; a quarter within 7 and three quarters within 33.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: primary completion Jan 2028 → May 2029 and completion Jan 2028 → Jun 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2024
First posted
Mar 15, 2024
StartActual
Mar 21, 2024
Primary completionEst.
May 28, 2029was Jan 2028
CompletionEst.
Jun 29, 2029was Jan 2028
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added
Show 2 added (2 United States)
  • GSK Investigational Site · Las Vegas, United States
  • GSK Investigational Site · Austin, United States
Nov 5, 2026
Primary completion
Jan 21, 2028→May 28, 2029
Nov 5, 2026
Study completion
Jan 21, 2028→Jun 29, 2029
Nov 5, 2026
Enrollment
372→348
Nov 5, 2026
Eligibility
2 inclusion criteria edited, 2 removed; 1 exclusion criterion edited, 2 added
What changed in the criteria
Inclusion criteria
  • Edited-Participant must be 18 to 55 years of age inclusive, at the time of signing the informed consent.
  • RemovedParticipants who are negative for SARS-CoV-2, performed on admission/readmission to the Phase 1 unit, using an approved molecular test (PCR).
  • RemovedWeight
  • EditedWeight -Body weight ≥50.0 kg (110 lbs) for men and ≥45.0 kg (99 lbs) for women and body mass index within the range 18.5 to 32.0 kg/m\^2 (inclusive) for all cohorts except B19. For Cohort B19, body mass index within the range >32.0 to 37.0 kg/m\^2 (inclusive).
Exclusion criteria
  • EditedReceipt of any live vaccine(s) or vaccines against SARS-CoV-2 within 28 days prior to screening or 14 days before or after scheduled SC or IM dosing.
  • AddedFasting glucose >125 mg/dL (6.95 mmol/L) or receiving treatment for elevated blood glucose.
  • AddedTriglycerides >500 mg/dL (5.7 mmol/L) or receiving treatment for dyslipidemia.
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    2 sites added
    Show 2 added (2 United States)
    • GSK Investigational Site · Las Vegas, United States
    • GSK Investigational Site · Austin, United States
    Primary completion Jan 21, 2028→May 28, 2029
    Study completion Jan 21, 2028→Jun 29, 2029
    Enrollment 372→348
    Eligibility 2 inclusion criteria edited, 2 removed; 1 exclusion criterion edited, 2 added
    What changed in the criteria
    Inclusion criteria
    • Edited-Participant must be 18 to 55 years of age inclusive, at the time of signing the informed consent.
    • RemovedParticipants who are negative for SARS-CoV-2, performed on admission/readmission to the Phase 1 unit, using an approved molecular test (PCR).
    • RemovedWeight
    • EditedWeight -Body weight ≥50.0 kg (110 lbs) for men and ≥45.0 kg (99 lbs) for women and body mass index within the range 18.5 to 32.0 kg/m\^2 (inclusive) for all cohorts except B19. For Cohort B19, body mass index within the range >32.0 to 37.0 kg/m\^2 (inclusive).
    Exclusion criteria
    • EditedReceipt of any live vaccine(s) or vaccines against SARS-CoV-2 within 28 days prior to screening or 14 days before or after scheduled SC or IM dosing.
    • AddedFasting glucose >125 mg/dL (6.95 mmol/L) or receiving treatment for elevated blood glucose.
    • AddedTriglycerides >500 mg/dL (5.7 mmol/L) or receiving treatment for dyslipidemia.
    + 3 other changes: identifiers, verification date and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06310551
Lead sponsor
ViiV Healthcare
Responsible party
Sponsor
First posted
Mar 15, 2024
Start date
Mar 21, 2024
Primary completion
May 28, 2029 (estimated)
Completion
Jun 29, 2029 (estimated)
Last update
Nov 5, 2026

Study contacts

US GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
877-379-3718
EU GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
+44 (0) 20 89904466

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: VH4524184

Start the discussion